CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Current care per UCLA treating physiciansWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2396 Reconsolidation of Traumatic Memories (RTM) Wiki 1.00
drug2244 Prolonged Exposure (PE) Wiki 1.00
drug705 Colchicine Tablets Wiki 0.58

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D000070642 Brain Injuries, Traumatic NIH 0.38
D001930 Brain Injuries, NIH 0.33
D040921 Stress Disorders, Traumatic NIH 0.19
D013313 Stress Disorders, Post-Traumatic NIH 0.18
D004194 Disease NIH 0.17

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)

Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm). Importantly, this adaptive trial design allows for patients in either study arm to receive other investigational drugs for COVID-19 as new science emerges.

NCT04355143 COVID-19 Drug: Colchicine Tablets Other: Current care per UCLA treating physicians

Primary Outcomes

Description: Number of participants experiencing any of the following: All-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)

Measure: Composite of all-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)

Time: 90 Days

Secondary Outcomes

Description: Change from initial troponin level to maximum level of troponin among measures taken during hospitalization and at 30 days

Measure: Delta (peak minus baseline) troponin level

Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized

Description: Change from baseline BNP level (Day 1) to maximum level of BNP among measures taken during hospitalization and at 30 days

Measure: Delta (baseline to peak) brain natriuretic peptide (BNP) level

Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized

Description: Number of participants experiencing LVEF of < 50% on echocardiogram with failure to show an improvement of ≥ 5% at 30 days

Measure: Change in left ventricular ejection fraction (LVEF) on echocardiography

Time: Baseline, Day 30

Measure: Delta (peak minus baseline) C-Reactive protein (CRP) inflammatory biomarker level

Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized

Description: D-Dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, so named because it contains two D fragments of the fibrin protein joined by a cross-link

Measure: Delta (peak minus baseline) D-Dimer inflammatory biomarker level

Time: Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized

Measure: Time (days) to primary endpoint

Time: up to 90 days

Measure: Number of participants requiring mechanical ventilation

Time: 90 days

Measure: Number of participants requiring mechanical circulatory support (MCS)

Time: 90 days

Description: Number of participants released and re-admitted to the hospital within 90 days of enrollment

Measure: Re-hospitalization at 90 days

Time: 90 days

Measure: All-cause mortality

Time: 90 days

No related HPO nodes (Using clinical trials)